Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CD19-CD34 CAR transduced T cells||Limited information is currently available on CD19-CD34 CAR transduced T cells (Apr 2023).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 17||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04214886||Phase I||CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine||CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies||Active, not recruiting||USA||0|